miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients

Enas M. Hefzy, Noha A. Hassuna, Olfat G. Shaker, Mohamed Masoud, Tebyan A. Abelhameed, Tarek I. Ahmed, Nada F. Hemeda, Mohammed A. Abdelhakeem, Rania H. Mahmoud

1 Faculty of Medicine, Department of Medical Microbiology and Immunology, Fayoum University, Fayoum, Egypt, 2 Faculty of Medicine, Department of Medical Microbiology and Immunology, Minia University, Minia, Egypt, 3 Faculty of Medicine, Department of Medical Biochemistry and Molecular Biology, Cairo University, Cairo, Egypt, 4 Faculty of Medicine, Department of Public Health, Fayoum University, Fayoum, Egypt, 5 Department of Biotechnology, Africa City of Technology, Khartoum, Sudan, 6 Faculty of Medicine, Department of Internal Medicine, Fayoum University, Fayoum, Egypt, 7 Faculty of Agriculture, Department of Genetics, Fayoum University, Fayoum, Egypt, 8 Faculty of Medicine, Department of Clinical Pathology, Minia University, Minia, Egypt, 9 Department of Medical Biochemistry and Molecular Biology, Fayoum University, Fayoum, Egypt

* emh01@fayoum.edu.eg

Abstract

Genetic variants in microRNAs (miRNAs) can alter the miRNAs expression and/or function, accordingly, affecting the related biological pathways and disease risk. Dysregulation of miR-155 and miR-146a expression levels has been well-described in viral hepatitis B (HBV). In the current study, we aimed to assess rs767649 T/A and rs57095329 A/G polymorphisms in miR-155, and miR-146a genes, respectively, as risk factors for Chronic HBV (CHBV) in the Egyptian population. Also, we aimed to do in silico analysis to investigate the molecules that primarily target these miRNAs. One hundred patients diagnosed as CHBV and one hundred age and sex-matched controls with evidence of past HBV infection were genotyped for miR-155 (rs767649) and miR-146a (rs57095329) using real-time polymerase chain reaction. The rs767649 AT and AA genotypes in CHBV patients confer four folds and ten folds risk respectively, as compared to control subjects [(AOR = 4.245 (95%CI 2.009–8.970), p<0.0001) and AOR = 10.583 (95%CI 4.012–27.919), p<0.0001, respectively]. The rs767649 A allele was associated with an increased risk of developing CHBV (AOR = 2.777 (95%CI 1.847–4.175), p<0.0001). There was a significant difference in the frequency of rs57095329 AG and GG genotypes in CHBV patients compared to controls. AG and GG genotypes showed an increase in the risk of developing CHBV by about three and six folds respectively [AOR = 2.610 (95%CI 1.362–5.000), p = 0.004] and [AOR = 5.604 (95%CI 2.157–14.563), p<0.0001]. We concluded that rs57095329 and rs767649 SNPs can act as potential risk factors for the development of CHBV in the Egyptian population.
Introduction

Infection by the hepatitis B virus (HBV) is one of the most common viral infections worldwide especially in developing countries [1]. In Egypt, HBV prevalence was 1.4% among ages ranged 15–59 in Egypt Health Issues Survey, 2015 [2]. In another survey in Southern Upper Egypt, about 4.4% of the studied population had chronic HBV (CHBV) [3]. In adults, less than 5% of infected healthy persons will develop chronic infections; and 20–30% of chronically infected adults will develop fibrosis, cirrhosis, and/or liver cancer [4]. Many factors can contribute to the progression of CHBV infection.

Genetics is considered as one of the most important factors influencing the clinical course of HBV infection. MicroRNAs (miR) are small non-coding ribonucleic acids formed nearly from 21–25 nucleotides that regulate the expression of protein-coding genes post-transcriptionally by affecting the translation and degradation of target mRNAs [5]. They regulate the host-virus interaction through suppression of viral infection pathways [6]. MiRNAs have a crucial role in the pathogenesis of various hepatic diseases, including chronic viral hepatitis [7].

Genetic variation in the regulatory regions in miRNAs could change their expression levels and this leads to phenotypic diversity [8]. Single nucleotide polymorphisms (SNPs) are variations in a single nucleotide that happen at a particular site in the DNA. SNPs in genes coding miRNAs (miR SNPs) have been found to affect the expression, processing, and functions of these miRNAs [9]. A strong association between these SNPs and disease progression, diagnosis, prognosis, and drug response has been reported [10].

The miR-155 was first found within the B-cell integration cluster non-coding RNA on chromosome 21 in the human genome [11]. It was reported that miR-155 plays an immense role in the regulation of host antiviral immunity and the development of HBV-associated liver diseases. It regulates the production of interferon against HBV via the JAK-STAT signaling and thus participates in innate antiviral immune responses [12]. The rs767649 is a functional variant found in the flanking region of the miR-155 gene that may lead to a poor prognosis and an increased risk of hepatocellular carcinoma [5].

The miR-146a gene resides on chromosome 5q33.3 [13]. The promoter of the miR-146a encoding gene has several binding sites for the nuclear factor- alpha B (NF-αB) transcription factor that plays a significant role in the immune response [14,15]. Unsurprisingly, numerous studies have implicated their association with the pathogenesis of autoimmune diseases [7]. Within the miR-146a gene, rs57095329 A/G in the promoter region is thought to reduce the expression levels of miR-146a [8]. Interestingly, miR-146a A/G SNP (rs57095329) has been associated with reducing the attachment to E26 transforming sequence 1 (ETS-1) transcription factor and affected the risk of systemic lupus erythematosus [9].

Dysregulation of the miR-146a and miR-155 expression levels has been well-described in viral hepatitis B [16]. However, it has not been reported yet, up to our knowledge, whether there is an association between the pathogenesis of CHBV infection and the miR-146a and miR-155 gene SNPs at loci rs57095329 A/G and rs767649 A/T respectively. We hypothesized that these potentially functional genetic variants may be associated with the progression of CHBV in the Egyptian population.

The current study aimed to assess these SNPs as risk factors for CHBV in the Egyptian population, as well as their relationship with the patients' clinical characteristics. Also, we aimed to do in silico analysis to explore the molecules that primarily targeted these miRNAs, and if rs57095329 A/G and rs767649 A/T may contribute to alterations in cellular function that ultimately lead to disease.
Results

Basic and clinical characteristics of study subjects

Table 1 shows the basic and clinical characteristics of the study groups. There was no statistically significant difference between cases and control as regards age (39.6±13 vs. 38.8±11.8, p = 0.661) and sex (p = 0.744).

Analysis of the frequency and association between miR-155 T/A polymorphism (rs767649) and miR-146a A/G (rs57095329) and susceptibility to CHBV viral infection

There was a statistically significant difference between the study groups regarding rs767649 genotype distribution as denoted by the Cochran-Armitage test for trend, p<0.0001. When compared to TT genotype (the normal genotype), there was about four folds risk of being CHBV when the patient has the mutant AT genotype; [AOR = 4.245 (95%CI 2.009–8.970), p<0.0001]. Moreover, there was about ten folds risk of being CHBV when the patient has the mutant AA genotype; [AOR = 10.583 (95%CI 4.012–27.919), p<0.0001]. The frequency of the AT and AA genotypes was higher in CHBV patients than in control (58% vs. 48%) and (30% vs. 10%), respectively (Table 2).

Table 1. Basic and clinical characteristics of study subjects.

|                      | Cases (N = 100) | Controls (N = 100) | P-value |
|----------------------|----------------|-------------------|---------|
| Mean ± SD            |                |                   |         |
| Age (years)          | 39.6±13        | 38.8±11.8         | 0.661   |
| BMI (kg/m²)          | 27.6±3.9       | 28.8±2.1          | 0.260   |
| Hb(g/dl)             | 13.5±1.9       | 13.2±1.2          | 0.688   |
| TLC (/mm³)           | 6442.8±2006.5  | 8500±1500.3       | <0.0001*|
| PLT (/mm³)           | 22000±98271    | 342000±1250       | <0.0001*|
| Creatinine (mg/dl)   | 0.9±0.2        | 0.8±0.3           | 0.077   |
| ALT(IU/L)            | 46.1±9.9       | 39.3±7.5          | <0.0001*|
| AST(IU/L)            | 41.2±7.2       | 32.7±6.4          | <0.0001*|
| Total Bilirubin (mg/dl) | 0.7±0.3       | 0.75±0.21         | <0.0001*|
| Albumin (g/dl)       | 4.2±0.6        | 4.6±0.45          | 0.006*  |
| INR                  | 1.1±0.3        | 0.8±0.2           | <0.0001*|
| Gender               |                |                   |         |
| Female (N%)          | 24(24.0)       | 26(26.0)          | 0.744   |
| Male                 | 76(76.0)       | 74(74.0)          |         |
| Viral load           |                |                   |         |
| <10 IU/mL            | 36(36.0)       |                   |         |
| ≥10 IU/mL            | 64(64.0)       |                   |         |
| Fibroscan(Transient elastography) |        |                   |         |
| F0                   | 42(42.0)       |                   |         |
| F1-F2                | 42(42.0)       |                   |         |
| F3-F4                | 16(16.0)       |                   |         |

*Statistical significance was considered at p-value ≤0.05; SD, standard deviation; BMI, body mass index; Hb, hemoglobin; TLC, total leukocyte count; PLT, Platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International Normalized Ratio; F0, No liver scarring; F1, Mild liver scarring; F2, Moderate liver scarring; F3, Severe liver scarring; F4, Advanced liver scarring.

https://doi.org/10.1371/journal.pone.0256724.t001
In the dominant model, there was about five folds risk of being CHBV when the patient had the mutant TT or AT genotypes, the AOR was 5.297 (95% CI 2.567–10.929), p < 0.0001. The frequency of the TT or AT genotypes was higher in CHBV than in control (88% vs. 58%) (Table 2).

In the recessive model participants with AA genotype had a higher risk, about three times, for being CHBV, the AOR was 3.841 (95% CI 1.748–8.438), (p = 0.001). The frequency of AA was higher in CHBV than in control (30% vs. 10%) (Table 2).

Patients with CHBV had a higher frequency of allele A than control (59% vs. 34%). The risk of CHBV increased by about two and a half [AOR = 2.777 (95%CI 1.847–4.175), p<0.0001] when the patients had allele A (Table 2).

As regards rs57095329, the genotypes distribution had a statistically significant difference between cases and control as denoted by the Cochran-Armitage test for trend, p<0.0001. As compared to the normal AA genotype, there was about two and a half folds risk of being CHBV when the patient has the AG genotype; [AOR = 2.610 (95%CI 1.362–5.000), p = 0.004]. Also, there was about five folds risk of being CHBV when the patient has GG genotype;

| Table 2. Analysis of the frequency and association between miR-155 T/A polymorphism (rs767649) and miR-146a A/G (rs57095329) and susceptibility to chronic hepatitis B viral infection. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Cases (N = 100) | Controls (N = 100) | Adjusted OR, (95% CI), p-value |
| N (%) | N (%) |
| rs767649 | | |
| TT | 12(12.0%) | 42(42.0%) | 4.245 (2.009–8.970), <0.0001* |
| AT | 58(58.0%) | 48(48.0%) | 5.297 (2.567–10.929), <0.0001* |
| AA | 30(30.0%) | 10(10.0%) | 10.583 (4.012–27.919), <0.0001* |
| Dominant | | |
| TT | 12(12.0%) | 42(42.0%) | |
| AT+AA | 88(88.0%) | 58(58.0%) | 5.297 (2.567–10.929), <0.0001* |
| rs57095329 | | |
| AA | 21(21.0%) | 45(45.0%) | |
| AG | 56(56.0%) | 46(46.0%) | 2.610 (1.362–5.000), 0.004* |
| GG | 23(23.0%) | 9(9.0%) | 5.604 (2.157–14.563), <0.0001* |
| Dominant | | |
| AA | 21(21.0%) | 45(45.0%) | |
| AG+GG | 79(79.0%) | 55(55.0%) | 3.061 (1.638–5.721), <0.0001* |
| rs767649 | | |
| T | 82(41.0%) | 132(66.0%) | |
| A | 118(59.0%) | 68(34.0%) | 2.777 (1.847–4.175), <0.0001* |
| Allele | | |
| T | 82(41.0%) | 132(66.0%) | |
| A | 118(59.0%) | 68(34.0%) | 2.777 (1.847–4.175), <0.0001* |
| rs57095329 | | |
| A | 98(49.0%) | 136(68.0%) | |
| G | 102(51.0%) | 64(32.0%) | 2.195 (1.456–3.308), <0.0001* |
| Allele | | |
| A | 98(49.0%) | 136(68.0%) | |
| G | 102(51.0%) | 64(32.0%) | 2.195 (1.456–3.308), <0.0001* |

*Statistical significance was considered at p value ≤0.05; OR, Odds Ratio; CI, Confidence interval; HWE in control: rs767649; chi-squared value = 0.483, p-value = 0.487; rs57095329; chi-squared value = 0.325, p-value = 0.569.

https://doi.org/10.1371/journal.pone.0256724.t002
[AOR = 5.604 (95%CI 2.157–14.563, p < 0.0001). The occurrence of AG and GG was higher in CHBV patients than in control (56% vs. 46%) and (23% vs. 9%), respectively (Table 2).

In the dominant model, there was about three folds risk of having CHBV when the patient was GG or AG as AOR was 3.061 (95%CI 1.638–5.721), (p < 0.0001). The frequency of GG or AG was higher in CHBV (78%) than in control (55%) (Table 2).

In the recessive model, participants with GG genotype had a higher risk, about three times, for being CHBV. The AOR was 3.078 (95%CI 1.311–7.231), (p = 0.01). The frequency of GG was higher in CHBV (22%) than in control (9%) (Table 2).

Patients with CHBV had a higher level of allele G than control (51% vs. 32%). The risk of CHBV increased by about two folds [AOR = 2.195 (95%CI 1.456–3.309, p < 0.0001] when the patients had allele G (Table 2).

Both polymorphisms were not deviated from HWE in control (p-value = 0.487 and p-value = 0.569 for rs767649 and rs57095329, respectively) (Table 2).

The miR-155 T/A polymorphism (rs767649) and the characteristics of cases with CHBV infection

As regards the relation between the miR-155 T/A polymorphism (rs767649) and the characteristics of cases with chronic hepatitis B viral infection, Table 3 shows that there were statistically significant differences between genotypes TT, AT, and AA regarding alanine aminotransferase (ALT) (39.7

| Table 3. The miR-155 T/A polymorphism (rs767649) to the characteristics of cases with chronic hepatitis B viral infection. |
|-----------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Genotype  | BMI (kg/m²)     | Hb(g/dl)       | TLC (/mm³)      | PLT (/mm³)      | Creatinine (mg/dl) | ALT(IU/L)       |
| TT (N = 12) | 27.6±3.8       | 13.5±0.8       | 5966.7±1285.8  | 189333.3±88046.8 | 0.8±0.2         | 39.7±13.4       |
| AT (N = 58) | 27.4±4.2       | 13±1.9         | 6495.2±2175.5  | 223896.6±11999.2 | 0.8±0.2         | 46.6±8.3        |
| AA (N = 30) | 28.1±3.4       | 13.9±2.1       | 6532±1925.3    | 224800±115047.9  | 0.9±0.3         | 47.7±10.4       |
| Mean±SD   |                |                |                |                | 0.048*          |                |

P-value: 0.572

| Genotype  | p-value   | Alleles | P-value |
|-----------|-----------|---------|---------|
| TT (N = 82) | 0.672     | T (N = 82) | 27.4±4.1   | 0.551 |
| AT (N = 118) | 0.102     | A (N = 118) | 27.8±3.8   | 0.976 |

| Gender | N (%) |
|--------|-------|
| Female | 0(0.00%) | 16(27.60%) | 8(26.70%) | 0.116 |
| Male   | 12(100.00%) | 42(72.40%) | 22(73.30%) | 66(80.5%) | 86(72.9%) |

Statistical significance was considered at p-value ≤0.05; BMI, body mass index; Hb, hemoglobin; TLC, total leukocyte count; PLT, Platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International Normalized Ratio; F0, No liver scarring; F1, Mild liver scarring; F2, Moderate liver scarring; F3, Severe liver scarring; F4, Advanced liver scarring (cirrhosis).

https://doi.org/10.1371/journal.pone.0256724.t003
±13.4, 46.6±8.3 vs. 47.7±10.4 IU/L respectively) (p = 0.048). There were no statistically significant differences between genotypes as regards other study parameters (p>0.05).

**The miR-146a A/G polymorphism (rs57095329) and the characteristics of cases with CHBV infection**

For the miR-146a A/G polymorphism (rs57095329) relation to the characteristics of cases with CHBV infection, there was a statistically significant relationship between sex and genotypes, p = 0.032. Regarding Hb, there was a statistically significant difference between the three genotypes; AA, AG, and GG (13.3±1.4, 13.1±2.0 vs. 14.6±1.8 g/dl respectively, p = 0.005).

Also, total bilirubin was significantly different between genotypes (0.6±0.3, 0.7±0.3 vs. 0.6±0.2 mg/dl respectively, p = 0.034). In contrast, there were no statistically significant differences between genotypes as regards other study parameters (p>0.05). Likewise, allele G had a higher level of Hb than allele A (13.7±2 vs. 13.2±1.7 g/dl respectively, p = 0.032) (Table 4).

**In silico analysis of the effect of rs767649 SNPs on miR-155 gene and miR-146a gene rs57095329 SNPs on the transcription factors (TFs) binding sites**

All data relating to the miR-155 rs767649 SNP and the miR-146a rs57095329 SNP were gathered from dbSNP in the National Center of Biotechnology Information database.

Table 4. The miR-146a A/G polymorphism (rs57095329) to the characteristics of cases with chronic hepatitis B viral infection.

| Genotype | Alleles | P-value | Genotype | Alleles | P-value |
|----------|---------|---------|----------|---------|---------|
| AA (N = 21) | AG (N = 56) | GG (N = 23) | P-value | AA (N = 98) | G (N = 102) | P-value |
| **Age** | Mean±SD | 37.0±11.5 | 38.9±12 | 44.8±15.7 | 0.174 | 38±11.7 | 41.1±13.8 | 0.094 |
| **BMI (kg/m²)** | Mean±SD | 26.9±4.2 | 27.5±3.9 | 28.5±3.5 | 0.433 | 27.3±4 | 27.9±3.7 | 0.232 |
| **Hb (g/dl)** | Mean±SD | 13.3±1.4 | 13.1±2 | 14.6±1.8 | 0.005* | 13.2±1.7 | 13.7±2 | 0.032 |
| **TLC (/mm³)** | Mean±SD | 6500.0±1956 | 6171.4±2130.3 | 7051.3±1647.9 | 0.208 | 6312.2±4 | 6568.2±1961.6 | 0.367 |
| **PLT (/mm³)** | Mean±SD | 215285.7±107695.0 | 208892.9±90745.3 | 251434.8±104682.6 | 0.212 | 211632.7±2 | 228078.4±98543.2 | 0.237 |
| **Creatinine (mg/dl)** | Mean±SD | 0.8±0.1 | 0.9±0.3 | 0.9±0.1 | 0.186 | 0.8±0.2 | 0.9±0.2 | 0.137 |
| **ALT(IU/L)** | Mean±SD | 45.0±7.9 | 47.4±9 | 44.0±13.1 | 0.329 | 46.3±8.5 | 45.8±11 | 0.709 |
| **AST(IU/L)** | Mean±SD | 40.6±5.2 | 41.5±5.8 | 41.0±11.1 | 0.884 | 41.1±5.6 | 41.3±8.5 | 0.882 |
| **Total Bilirubin (mg/dl)** | Mean±SD | 0.6±0.3 | 0.7±0.3 | 0.6±0.2 | 0.034* | 0.66±0.29 | 0.69±0.25 | 0.319 |
| **Albumin (g/dl)** | Mean±SD | 4.4±0.3 | 4.1±0.8 | 4.3±0.3 | 0.087 | 4.2±0.7 | 4.2±0.6 | 0.760 |
| **INR** | Mean±SD | 1.2±0.5 | 1.1±0.1 | 1±0.1 | 0.096 | 1.1±0.4 | 1.1±0.1 | 0.053 |

| Gender | N (%) | N (%) |
|--------|-------|-------|
| Female | 5(23.80) | 18(32.10) | 1(4.30) | 0.032* | 28(28.60) | 20(19.60) | 0.138 |
| Male | 16(76.20) | 38(67.90) | 22(95.70) | 0.034* | 70(71.40) | 82(80.40) |

| Viral Load | N (%) | N (%) |
|------------|-------|-------|
| <10 IU/mL | 7(33.3) | 22(39.3) | 7(30.4) | 0.727 | 36(36.7) | 36(35.3) | 0.832 |
| ≥10 IU/mL | 14(66.7) | 34(60.7) | 16(69.6) | 0.066 | 62(63.3) | 66(64.7) | 0.302 |

| Fibroscan(Transient elastography) | N (%) | N (%) |
|-----------------------------|-------|-------|
| F0 | 5(23.8) | 26(46.4) | 11(47.8) | 0.034* | 36(36.7) | 48(47.1) | 0.302 |
| F1-F2 | 14(66.7) | 18(32.1) | 10(42.5) | 46(46.9) | 38(37.3) |
| F3-F4 | 2(9.5) | 12(21.4) | 2(8.7) | 16(16.3) | 16(15.7) |

*Statistical significance was considered at p-value <0.05; BMI, body mass index; Hb, hemoglobin; TLC, total leukocyte count; PLT, Platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International Normalized Ratio; F0, No liver scarring; F1, Mild liver scarring; F2, Moderate liver scarring; F3, Severe liver scarring; F4, Advanced liver scarring (cirrhosis).

https://doi.org/10.1371/journal.pone.0256724.t004
The miR-155 is located on chromosome 21 in humans. The miR-155 rs767649 SNP located in the promoter region of the miR-155 gene in which the T allele is replaced by A allele, while the miR-146a located in chromosome 5, and the miR-146a rs57095329 SNP located in the promoter region of miR-146a gene in which A allele replaced by G allele. Accordingly, both SNPs were analyzed using Regulome DB, Haploreg, and Alibaba software.

According to Regulome DB software, the rs767649 can affect the binding sites of IRF1 (the interferon regulatory factor); IRF2, and PRDM1 (PR domain zinc finger protein 1), while rs57095329 SNP could affect the binding sites ELF3 (E74 Like ETS Transcription Factor 3). The Haploreg software showed that the rs767649 affects the binding sites of IRF, MRG1 (melanocyte-specific gene-related gene 1), HOXA9 (Homeobox A9), and PRDM1 and the rs57095329 SNP affected the binding sites of ETS (E26 transforming sequence), PAX-5 (a member of the paired box (PAX) family of transcription factors), and STAT (signal transducer and activator of transcription).

On other hand, Haploreg predicted the reference and altered sequences (S1 Table) which were used in Alibaba software as FASTA format showing the effect of both SNPs on some TFs binding sites. According to Alibaba software, the GCN4 (General control protein) binding site was affected with A allele (mutant allele) and was not affected with the T allele (normal allele) of rs767649 SNP. However, MyoD (myoblast determination protein 1) and ETS-1 binding site was altered in case of G allele (mutant allele) of rs57095329 SNP. In general, it was concluded that the rs767649 SNP affected mainly the IRF and PRDM1 TFs binding sites and the rs57095329 affected the binding sites of the ETS family of TFs. The predicted transcription factors binding sites affected by miR-155 rs767649 and miR-146a rs57095329 using Regulome DB, Haploreg and Alibaba software are represented in S2 Table.

**Discussion**

One of the main concerns of the CHBV research groups is to define the molecular factors involved in its development. Several studies have documented that viral infections alter the profiles of host miRNAs, which can influence virus-host interfaces and contributes to viral pathogenesis [17].

Presently, the available data suggest that miRNAs are implicated in both the HBV life cycle and the development of HBV-associated liver diseases [18].

It has been outlined that miR-155 is a transactivational target of nuclear factor kappa B (NF-κB), the NF-κB upregulates miR-155. The upregulated miR-155, through its target inhibitor of nuclear factor kappa-B kinase subunits beta and epsilon (IKKB and IKKe), leads to the limitation of NF-κB [19]. The NF-κB is a key regulator that shares in "the inflammation–fibrosis–cancer process", and the NF-κB signaling pathway seems to have an essential effect on liver homeostasis, pathophysiology, and regulation of the inflammation–fibrosis–cancer axis [20].

Typically, miR-155 is implicated in defensive immunity when adequately regulated and acts within a range of active immune cell types like T cells, B cells, and natural killer cells [21]. In the current study, we found a statistically significant difference between study groups in the miR-155 T/A (rs767649) SNP, as the patients with the homozygous AA genotype were at 10 fold risk of progression to CHBV and those with heterozygous AT genotype showed a four-fold risk of CHBV development with the A allele being a significant risk factor. Since miR-155 expression levels are lower with the AA genotype [5], our findings are consistent with Sarkar et al and Ge et al, who found that miR-155 is down-regulated in peripheral mononuclear cells in the blood of patients with CHBV infection [22,23].
Generally, several reports have shown that the expression level of miR-146a is influenced by two functional SNPs, rs57095329 A/G, and rs2910164 G/C in the gene encoding miR-146a, resulting in a genetic tendency to different diseases [9,24,25]. The association between the levels of miR-146a and liver disorders was previously stated. MiR-146a up-regulation may lead to dysfunction of HBV-specific T cells with subsequent viral persistence [26]. Furthermore, miR-146a levels were elevated in HBV-loaded Huh-7 hepatocytes (used as a hepatocyte culture model), as well as in both mice and patients infected with HBV [27].

In the current work, both the mutant GG and AG genotypes of rs57095329 in miR-146a were associated with a significantly increased risk of developing CHBV than the normal AA genotype. It is known that expression levels of miR-146a with the rs57095329 increase in AA patients compared to GG/GA patients [28]. Our findings are thus consistent with Wen et al [29], who found that miR-146a levels are lower in CHBV compared to acute or chronic liver failure and that miR-146a levels are proportionally related to the severity of liver inflammation. This is due to the immune-modulating effect induced by miR-146a on both innate and adaptive immune responses by negative feedback loops inducing down-regulation of their gene products [30].

The effectors of miR-146a are highly variable depending on the cell type as well as different disease conditions including tumor necrosis factor receptor-associated factor 6, complement factor H, and different toll-like receptor signaling pathways [14,27,31].

Since miR-155 and miR-146a activate several essential signaling proteins as well as transcription factors that control different immune processes and differentiation, it is not shocking that they have a pivotal role during immune responses to HBV infection.

The interaction between TFs and miRNAs in a regulatory network has not been discovered yet. In this study we aimed to do in silico analysis to investigate the molecules that primarily target these miRNAs, and if rs767649 T/A and rs57095329 A/G polymorphisms may contribute to alterations in the cellular function that ultimately lead to disease. Generally, we found that the rs767649 SNP affected mainly its interaction with IRF and PRDM1 transcription factors, and the rs57095329 affected its interaction with the ETS family of TFs.

The investigation of the interaction between these miRNAs and the retrieved TFs is not in the scope of this paper because it is not easy to revise the regulatory mechanisms of both TFs and miRNAs even at the data level, as it is too difficult to accomplish a network involving genes, TFs and miRNAs [32]. Also, these predictable networks may not completely expose the multifaceted gene-regulatory mechanisms, such as, the mode in which a TF indirectly controls a gene through a miRNA. However, the bioinformatics findings of this study can highlight the importance of their study in CHBV patients which is a challenge as the combined regulation of miRNAs and TFs in these cases is expected to be complicated, given that they include not only the relations between these regulatory elements and their target genes but also the interactions between the regulatory elements themselves [32].

To the best of the authors’ knowledge, the present research is the first to note a positive relationship between miR-155 rs767649 and miR-146a rs57095329 SNPs and risk of CHBV and it is the first study done on Egyptian patients as well.

There were some limitations to the current analysis. There was unavoidable selection bias because of the hospital-based as well as the case-control design of the research. Also, there was a lack of evidence on other genetic and environmental risk factors that would lead to the development of CHBV in those individuals, and gene-gene and gene-environment associations could not be analyzed.
Conclusion

SNPs in miR-155 rs767649 and miR-146a rs57095329 are associated with the risk of development of CHBV in Egyptian patients. Such novel results will be of clinical significance and could illuminate the role of miR-155 and miR-146a in the pathogenesis of CHBV.

Subjects and methods

Study subjects, and laboratory analyses

This case-control study included 100 patients who had confirmed CHBV infection, and 100 age and sex-matched controls with evidence of past HBV infection. All studied subjects were Egyptians. Patients were recruited from the outpatient clinic, Department of Internal Medicine, Faculty of Medicine, Fayoum University.

All study subjects had complete history taking: personal history, disease history (onset, course, and duration of the disease), medical history (other systemic disorders, and systemic treatment), physical examination, routine laboratory investigations as complete blood count, renal function tests, and liver function tests.

Cases. According to the Centers for Disease prevention and control, a case of CHBV was identified by the absence of anti-HBc IgM (immunoglobulin M antibodies to HBV core antigen) and a positive result for any one of the following: HBsAg (hepatitis B surface antigen), HBeAg (hepatitis B e-antigen), or hepatitis B virus DNA (either quantitative, qualitative and genotype testing) [33].

In this study, the chronic infection was diagnosed with detectable immunoglobulin G (IGg) anti-HBc and/or fibroscan (transient elastography), and any clinical findings compatible with chronic liver disease. Serum HBsAg, anti-HBs, and anti-HBc were assayed by enzyme-linked immunosorbent assay (ELISA) in the serum isolated from peripheral blood (Bioelisa, Biokit, Barcelona, Spain), according to the manufacturer’s instruction.

Control subjects

Control subjects (CSs) who had past HBV infection (negative for HBsAg and positive for both anti-HBs and anti-HBc), with normal liver function tests were collected in the same period. Those who had a history of HBV vaccination or were tested negative for anti-HBc and positive for anti-HBs were excluded from the study.

Informed written consent was collected from all the enrolled subjects at recruitment after a detailed, simplified explanation of the study. The study was approved by the research ethical committee, Faculty of Medicine, Fayoum University, and proceeded in agreement with the Helsinki declaration approved at the World Medical Association meeting in Edinburgh.

All the study subjects did not have a history of other liver diseases. The study subjects (patients or CSs) were excluded from the study in the following cases: 1) tested positive for anti-HIV or anti-HCV antibodies (Bioelisa, Biokit, Barcelona, Spain); 2) extreme alcohol consumption or smoking (smokes ≥1 cigarette pack(s)/daily, and 3) presence of other types of hepatic disorders, such as primary biliary cirrhosis, autoimmune hepatitis, hepatic carcinoma, non-alcoholic steatohepatitis, hemochromatosis, toxic hepatitis, Wilson’s disease, Budd-Chiari syndrome or α-1 antitrypsin deficiency. None of the patients had previous history of immunosuppressant, or anti-viral treatment.

The sample size was calculated using (G power version 3). The minimal sample size of patients was 100 in each group needed to get power level 0.80, alpha level 0.05, and 15% as an expected difference in the proportion of subjects with TT in rs767649 between cases and control (25% vs.10%).
Blood sample and Genomic DNA extraction

Venous blood samples were collected from 100 patients with CHBV infection, and 100 control subjects. One part of the sample was used for routine laboratory investigations and the other part was collected in EDTA tubes for DNA extraction from the whole blood and was stored at -80˚C until further analysis. Genomic DNA was extracted from the peripheral blood samples using the QIAamp DNA Blood Mini kit (QIAamp; Qiagen, Hilden, Germany) following the manufacturer’s instructions. Quantitation of DNA was done utilizing the NanoDrop1-1000 spectrophotometer (NanoDrop innovations, Inc., Wilmington, USA). The HBV viral load (copies/mL) was assessed by real-time PCR (Rotor-gene Q Real-Time PCR system, Qiagen) using an Artus HBV RG qPCR Kit (Qiagen), which has a detection limit of 10 IU/mL, according to the manufacturer’s instructions.

Genotyping

The miR-146a rs57095329 (A/G) and miR-155 rs767649 (T/A) polymorphisms were genotyped by real-time PCR (RT-PCR) using the customized TaqMan SNP Genotyping Assays; (C_2212229_10) for miR-155 rs767649 T>A and (C_90078480_10) miR-146a rs57095329 A>G (Applied Biosystems Thermo Fisher Scientific, Foster City, CA, USA) according to the manufacturer’s protocol.

The sequences of the primers used were: miR-155 rs767649 forward, 5'-ATATAACACATTATCAAAAACACTGAG-3' and reverse, 5’-CACCTTTCTGAGTGCTCTAATCAGG-3'; and miR-146a rs57095329 forward 5’-CCCACGGGGCTGAGGAGAGTACAG-3’ and reverse, 5’-CAGGAAAGCCTGAGGACCCAGCGCCT-3’.

Reactions were performed in a real-time PCR thermal cycler (Rotor-gene Q Real-Time PCR system, Qiagen). For amplification, reaction tubes were heated for 10 min at 95˚C, followed by 45 cycles of 92˚C for 15 s and 60˚C for 90 sec.

Although real-time PCR is not the gold standard for genotyping polymorphisms; nowadays, it is the most commonly used technique in epidemiological studies involving a large number of subjects and frequencies of known polymorphisms. Genotyping quality control was performed in 10% of the samples, the amplification reactions were performed twice. By double-checking, a 100% rate of concordance between duplicates was found.

In silico analysis of miR-155 rs767649 (T/A) polymorphisms and miR-146a rs57095329 (A/G)

These websites were used to analyze the miR-155 rs767649 (T/A) and miR-146a rs57095329 (A/G) SNPs:

Regulome DB. Is a database that marks up well-known and predicted SNPs and their relationship with regulatory factors in the intergenic regions of the genome. The reported regulatory DNA factors include the promoter regions that regulate transcription, transcription factors binding sites, and DNase hypersensitivity regions. The sources of data for the Regulome DB database were the published literature, public datasets from GEO, and the ENCODE project [34]. Regulome DB is available at [https://regulome.stanford.edu/regulome-search/](https://regulome.stanford.edu/regulome-search/).

HaploReg v4.1. HaploReg is available at [https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php](https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php).

HaploReg website is a tool to read the non-coding genome at genotype block variants, such as SNPs located at disease-associated loci. It uses the linkage disequilibrium data from the 1000 Genomes Project. It can see protein binding sites, linked SNPs, chromatin state, small
indels, SNPs effect on regulatory motifs, and SNPs effect on the expression from eQTL studies sequences conserved across mammals [35].

**Alibaba 2.1.** The putative transcription factor binding sites were detected within the empirically defined proximal promoters using AliBaba 2.1 (http://gene-regulation.com/pub/programs/alibaba2/index.html), which is based on the TRANSFAC 3.5 database [36].

**Statistical analysis**

Divergence from Hardy-Weinberg equilibrium was tested for each polymorphism using Pearson’s Chi-square test by a specific calculator; available online at http://www.oege.org/software/hardy-weinberg.html. The collected data were statistically examined using SPSS (software statistical computer package) version 22 (SPSS Inc, USA). For quantitative data (clinical and laboratory characteristics), the mean and standard deviation (SD) were calculated. Independent-t-test or One way ANOVA was used in the comparison between any two groups or three groups, respectively. Qualitative data were presented as numbers and percentages, chi-square ($\chi^2$) was used as a test of significance. The Cochran-Armitage test for trend was used to evaluate the differences in the distribution of genotype between cases and controls. Adjusted Odds ratio (AOR) with 95% confidence intervals (CI) for the association of the study groups with different models and allelic frequency of the miR-146a A/G (rs57095329) and miR-155 T/A (rs767649) genotypes were calculated using univariate and multivariate logistic regression. For interpretation of the results of tests of significance, significance was adopted at $p \leq 0.05$.

**Supporting information**

S1 Table. Predicted reference and altered sequence of miR-155 gene and miR-146a gene using Haploreg software.

S2 Table. Predicted transcription factors binding sites affected by miR-155 rs767649 and miR-146a rs57095329 using Regulome DB, Haploreg and Alibaba software.

**Author Contributions**

**Conceptualization:** Enas M. Hefzy, Noha A. Hassuna, Olfat G. Shaker, Tarek I. Ahmed, Nada F. Hemeda, Rania H. Mahmoud.

**Data curation:** Enas M. Hefzy, Olfat G. Shaker, Mohamed Masoud, Tebyan A. Abelhameed.

**Formal analysis:** Mohamed Masoud, Tebyan A. Abelhameed.

**Investigation:** Enas M. Hefzy, Olfat G. Shaker, Tarek I. Ahmed, Nada F. Hemeda, Mohammed A. Abdelhakeem, Rania H. Mahmoud.

**Methodology:** Enas M. Hefzy, Noha A. Hassuna, Olfat G. Shaker, Nada F. Hemeda, Mohammed A. Abdelhakeem.

**Project administration:** Enas M. Hefzy, Rania H. Mahmoud.

**Resources:** Nada F. Hemeda, Rania H. Mahmoud.

**Software:** Tebyan A. Abelhameed.

**Supervision:** Enas M. Hefzy, Olfat G. Shaker, Rania H. Mahmoud.

**Validation:** Mohamed Masoud, Tarek I. Ahmed, Nada F. Hemeda.
Writing – original draft: Enas M. Hefzy, Noha A. Hassuna, Tebyan A. Abelhameed, Tarek I. Ahmed, Rania H. Mahmoud.

Writing – review & editing: Enas M. Hefzy, Noha A. Hassuna, Mohamed Masoud, Mohamed A. Abdelhakeem, Rania H. Mahmoud.

References

1. Chang SW, Fann CS, Su WH, Wang YC, Weng CC, Yu CJ, et al. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PloS one. 2014 Jun 18; 9(6): e99724. https://doi.org/10.1371/journal.pone.0099724 PMID: 24940741

2. Chun HW, Hong R. Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncol. Lett. 2016 Sep 1; 12(3):1753–62. https://doi.org/10.3892/ol.2016.4884 PMID: 27602109

3. Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011 Apr 1; 157(4):163–79. https://doi.org/10.1016/j.trsl.2011.01.007 PMID: 21420027

4. Ismail SA, Cuadros DF, Benova L. Hepatitis B in Egypt: A cross-sectional analysis of prevalence and risk factors for active infection from a nationwide survey. Liver Int. 2017 Dec; 37(12):1814–22. https://doi.org/10.1111/liv.13469 PMID: 28481452

5. Ji J, Xu M, Tu J, Zhao Z, Gao J, Chen M, et al. MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma. Oncotarget. 2016 Sep 13; 7(37):60303. https://doi.org/10.18632/oncotarget.11206 PMID: 27531892

6. Knight JC. Regulatory polymorphisms underlying complex disease traits. "J. Mol. Med. 2005 Feb 1; 83(2):97–109. https://doi.org/10.1007/s00109-004-0603-7 PMID: 15592805

7. Li C, Fu W, Zhang Y, Zhou L, Mao Z, Lv W, et al. Meta-analysis of microRNA-146a rs2910164 G>C polymorphism association with autoimmune diseases susceptibility, an update based on 24 studies. PloS one. 2015 Apr 1; 10(4):e0121918. https://doi.org/10.1371/journal.pone.0121918 PMID: 25830862

8. Löfgren SE, Frostegård J, Truedsson L, Pons-Estel BA, D’Alfonso S, Witte T, et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012 Apr; 13(3):268–74. https://doi.org/10.1038/gene.2011.84 PMID: 22218224

9. Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011 Jun 30; 7(6):e1002128. https://doi.org/10.1371/journal.pgen.1002128 PMID: 21738483

10. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology, and individualized medicine.

11. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007 Apr 27; 316(5824):608–11. https://doi.org/10.1126/science.1139253 PMID: 17463290

12. Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol. J. 2011 Dec; 8(1):1–1. https://doi.org/10.1186/1743-422X-8-354 PMID: 21762537

13. Yan P, Xia M, Gao F, Tang G, Zeng H, Yang S, et al. Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2015; 8(11):15177. PMID: 26823863

14. Rusca N, Monticelli S. MiR-146a in immunity and disease. Mol bio internat. 2011;2011. https://doi.org/10.4061/2011/437301 PMID: 22091404

15. Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front. Immunol. 2014 Nov 21; 5:578. https://doi.org/10.3389/fimmu.2014.00578 PMID: 2548482

16. Yang Z, Peng Y, Yang S. MicroRNA-146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin-6. Exp Ther Med. 2019 Jun 1; 17(6):4670–6. https://doi.org/10.3892/etm.2019.7490 PMID: 31086599

17. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005 Mar; 5(3):215–29. https://doi.org/10.1038/nr1573 PMID: 15738952

18. Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol. 2018 Sep 27; 10(9):558. https://doi.org/10.4254/wjh.v10.i9.558 PMID: 30310534
19. Elfaki I, Mir R, Mir MM, AbuDuhier FM, Babakr AT, Barnawi J. Potential impact of microRNA gene polymorphisms in the pathogenesis of diabetes and atherosclerotic cardiovascular disease. J. Pers. Med. 2019 Dec; 9(4):51. https://doi.org/10.3390/jpm9040051 PMID: 31775219

20. Sun B, Karin M. NF-κB signaling, liver disease and hepatoprotective agents. Oncogene. 2008 Oct; 27 (48):6228–44. https://doi.org/10.1038/onc.2008.300 PMID: 18931690

21. Vigoreto E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immuno- noirev. 2013 May; 253(1):146–57. https://doi.org/10.1111/imr.12057 PMID: 23550644

22. Sarkar N, Panigrahi R, Pal A, Biswas A, Singh SP, Kar SK, et al. Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes. J Viral Hepat. 2015 Oct; 22(10):817–27. https://doi.org/10.1111/jvh.12390 PMID: 25720442

23. Ge J, Huang Z, Liu H, Chen J, Xie Z, Chen Z, et al. Lower expression of MicroRNA-155 contributes to dysfunction of natural killer cells in patients with chronic hepatitis B. Front Immunol. 2017 Sep 22; 8:1173. https://doi.org/10.3389/fimmu.2017.01173 PMID: 29018442

24. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008 May 20; 105(20):7269–74. https://doi.org/10.1073/pnas.0802682105 PMID: 18474871

25. Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L, et al. MicroRNA -146a and Ets-1 gene polymorphisms in ocular Behçet’s disease and Vogt–Koyanagi–Harada syndrome. Ann Rheum Dis. 2014 Jan 1; 73 (1):170–6. https://doi.org/10.1136/annrheumdis-2012-201627 PMID: 23268366

26. Wang S, Zhang X, Ju Y, Zhao B, Yan X, Hu J, et al. MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B. J. Immunol. 2013 Jul 1; 191 (1):293–301. https://doi.org/10.4049/jimmunol.1202100 PMID: 23697495

27. Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. MBio. 2015 May 1; 6(2). https://doi.org/10.1128/mBio.02459-14 PMID: 25805734

28. Shao Y, Li J, Cai Y, Xie Y, Ma G, Li Y, et al. The functional polymorphisms of miR-146a are associated with susceptibility to severe sepsis in the Chinese population. Mediators Inflamm. 2014 Oct;2014. https://doi.org/10.1155/2014/916202 PMID: 24701036

29. Wen Y, Peng SF, Fu L, Fu XY, Wu DX, Liu BJ, et al. Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure. (HPBD INT 2018 Apr 1; 17(2):126–32. https://doi.org/10.1016/j.hbpd.2018.03.004 PMID: 29602672

30. Labbaye C, Testa U. The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J. Hematol. Oncol. 2012 Dec; 5(1):1–0. https://doi.org/10.1186/1756-8722-5-13 PMID: 22453030

31. Li L, Chen XP, Li YJ. MicroRNA-146a and human disease. Scand J Immunol 2010 Apr; 71(4):227–31. https://doi.org/10.1111/j.1365-3083.2010.02383.x PMID: 20384865

32. Le TD, Liu L, Liu B, Tsykin A, Goodall GJ, Satou K, et al. Inferring microRNA and transcription factor regulatory networks in heterogeneous data. BMC bioinformatics. 2013 Dec; 14(1):1–3. https://doi.org/10.1186/1471-2105-14-92 PMID: 23497388

33. Dakic Z, Duric P, Fabri M, O’May F. Validity of hepatitis B and hepatitis C case definitions. J Infect Public Health. 2019 1; 12(4):516–21. https://doi.org/10.1016/j.jiph.2019.01.061 PMID: 30772265

34. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002 Jan 1; 2(1):S1–5. PMID: 11808873

35. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res.2012 Jan 1; 40(D1):D930–4.

36. Boyle AP, Hong EL, Harirhan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome res. 2012 Sep 1; 22(9):1790–7. https://doi.org/10.1101/gr.137323.112 PMID: 22955989